Induction of Anti-Tumor Immunity by Trifunctional Antibodies in Patients with Peritoneal Carcinomatosis
Author Information
Author(s): Ströhlein Michael A, Siegel Robert, Jäger Michael, Lindhofer Horst, Jauch Karl-Walter, Heiss Markus M
Primary Institution: Witten/Herdecke University
Hypothesis
Can trifunctional antibodies induce anti-tumor specific T-lymphocytes in patients with peritoneal carcinomatosis?
Conclusion
Trifunctional antibodies can induce anti-tumor immunity in patients with peritoneal carcinomatosis, leading to clinical responses and improved survival.
Supporting Evidence
- Five out of nine patients showed a significant increase in tumor reactive T-lymphocytes after treatment.
- Clinical responses were observed in five out of nine patients, with a mean time to progression of 3.6 months.
- Mean survival after treatment was 11.8 months, with a median of 8.0 months.
Takeaway
This study shows that a special type of medicine called trifunctional antibodies can help the body fight cancer by making special immune cells that attack tumors.
Methodology
Patients received escalating doses of trifunctional antibodies after surgery and were restimulated with autologous tumor cells to evaluate immune response.
Potential Biases
Potential bias due to the small sample size and lack of a control group.
Limitations
The study involved a small number of patients and was a pilot study, limiting the generalizability of the results.
Participant Demographics
Patients had progressive peritoneal carcinomatosis from gastric and ovarian cancer, with varying prior treatments.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website